The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Zolpidem for insomnia
Abstract
INTRODUCTION: The imidazopyridine derivative zolpidem , which acts as a benzodiazepine (BZ) receptor agonist, is the most widely prescribed hypnotic drug in the US. AREAS COVERED: This review addresses the neuroreceptor properties of zolpidem; clinical pharmacokinetics, pharmacodynamics and drug interactions; efficacy as a hypnotic; adverse effects; tolerance, dependence and withdrawal; relation to motor vehicle accidents and complex sleep behaviors; and new dosage forms. EXPERT OPINION: Approved doses of zolpidem (10 mg for adults, 5 mg for the elderly) are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia. However, favorable effects on sleep maintenance are observed less consistently. Residual daytime effects are unlikely with recommended doses, and provided that at least 8 h elapse prior to arising. Hypnotic efficacy is maintained with repeated nightly use, and the risk of rebound insomnia is low. Dependence and abuse of zolpidem are no more likely to occur than with typical benzodiazepines. Newly available novel dosage forms of zolpidem have increased therapeutic options for patients with insomnia variants such as sleep maintenance insomnia and middle-of-the-night awakening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161 · cited 1×
“2 Interpretation of clinical trials The large clinical trials database has been the subject of previous reviews and meta-analyses [1-5,57-63].”
BackgroundGABAA receptors: Subtypes provide diversity of function and pharmacology
Olsen, R. W., & Sieghart, W. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.045 · Cited by 982
Aging Biology and Geriatric Clinical Pharmacology
McLean, A. J., & Le Couteur, D. G. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.4 · Cited by 771
Driver sleepiness and risk of serious injury to car occupants: population based case control study
Connor, J., Norton, R., Ameratunga, S., Robinson, E., Civil, I., Dunn, R., Bailey, J., & Jackson, R. (2002) · BMJ · doi:10.1136/bmj.324.7346.1125 · Cited by 748
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 1×
“Most, but not all [13], neurochemical studies of zolpidem indicate that the drug has relatively selective affinity for the BZ-1 (omega-1) receptor subtype, corresponding to the population containing alpha-1 subunits [14-20].”
BackgroundPrevalence, burden, and treatment of insomnia in primary care
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.10.1417 · Cited by 694 · cited 1×
“Insomnia is prevalent in the population, either as a primary entity, or more commonly, coincident with a medical or psychiatric sleep or circadian disorder [136-140].”
BackgroundInsomnia and the Performance of US Workers: Results from the America Insomnia Survey
Kessler, R. C., Berglund, P. A., Coulouvrat, C., Hajak, G., Roth, T., Shahly, V., Shillington, A. C., Stephenson, J. J., & Walsh, J. K. (2011) · Sleep · doi:10.5665/sleep.1230 · Cited by 527
Self-citationGABAA receptor subtypes: dissecting their pharmacological functions
Rudolph, U., Crestani, F., & Möhler, H. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01646-1 · Cited by 471
Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451
The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs
Buscemi, N., Vandermeer, B., Friesen, C., Bialy, L., Tubman, M., Ospina, M., Klassen, T. P., & Witmans, M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0251-z · Cited by 448 · cited 1×
“2 Interpretation of clinical trials The large clinical trials database has been the subject of previous reviews and meta-analyses [1-5,57-63].”
BackgroundHajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404 · cited 2×
“Some experimental data and clinical reports suggest that zolpidem may have a lower risk of dependence, abuse, and misuse than other typical benzodiazepines [75-81].”
BackgroundAvidan, A. Y., Fries, B. E., James, M. L., Szafara, K. L., Wright, G. T., & Chervin, R. D. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53304.x · Cited by 343
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Insomnia causes, consequences, and therapeutics: An overview
Drake, C. L., Roehrs, T., & Roth, T. (2003) · Depression and Anxiety · doi:10.1002/da.10151 · Cited by 308
Self-citationMechanism of action of the hypnotic zolpidem in vivo
Crestani, F., Martin, J. R., Möhler, H., & Rudolph, U. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703717 · Cited by 307
Road accidents caused by drivers falling asleep
Sagberg, F. (1999) · Accident Analysis & Prevention · doi:10.1016/s0001-4575(99)00023-8 · Cited by 301
Zolpidem: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential
Langtry, H. D., & Benfield, P. (1990) · Drugs · doi:10.2165/00003495-199040020-00008 · Cited by 297
Fatigue, Sleepiness, and Performance in Simulated Versus Real Driving Conditions
Philip, P., Sagaspe, P., Taillard, J., Valtat, C., Moore, N., Åkerstedt, T., Charles, A., & Bioulac, B. (2005) · Sleep · doi:10.1093/sleep/28.12.1511 · Cited by 294
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Self-citationKupfer, D. J., & Reynolds, C. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360506 · Cited by 287
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem: Therapeutic Implications
Salvà, P., & Costa, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00002 · Cited by 273
Zolpidem Use and Hip Fractures in Older People
Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2001.49280.x · Cited by 272
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
Epidemiology of Medication-Related Falls and Fractures in the Elderly
Cumming, R. G. (1998) · Drugs & Aging · doi:10.2165/00002512-199812010-00005 · Cited by 254
Drover, D. R. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443040-00002 · Cited by 248
Limitations and strengths of spontaneous reports data
Goldman, S. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80007-6 · Cited by 242
Verster, J., & Roth, T. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s19639 · Cited by 237
Self-citationAllain, H., Bentu??-Ferrer, D., Polard, E., Akwa, Y., & Patat, A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522090-00004 · Cited by 214
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212
Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., & Roth, T. (2008) · Sleep · doi:10.1093/sleep/31.1.79 · Cited by 212
Self-citationComparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes
Sanna, E., Busonero, F., Talani, G., Carta, M., Massa, F., Peis, M., Maciocco, E., & Biggio, G. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02191-x · Cited by 208
Victorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201
Gustavsen, I., Bramness, J. G., Skurtveit, S., Engeland, A., Neutel, I., & Mørland, J. (2008) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.011 · Cited by 201
Zolpidem: Distinct from Triazolam?
Lobo, B. L., & Greene, W. L. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100518 · Cited by 200
Sateia, M. J., & Nowell, P. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17480-1 · Cited by 190
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121030-00002 · Cited by 182
Self-citationKrystal, A. D. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.08.001 · Cited by 180
Residual effects of sleep medication on driving ability
Verster, J. C., Veldhuijzen, D. S., & Volkerts, E. R. (2004) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.02.001 · Cited by 178
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00003 · Cited by 177
Self-citationHypnosedative-Induced Complex Behaviours: Incidence, Mechanisms and Management
Dolder, C. R., & Nelson, M. H. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00005 · Cited by 172
The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents
Sanger, D. J. (2004) · CNS Drugs · doi:10.2165/00023210-200418001-00004 · Cited by 168
Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.594 · Cited by 168
Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans, S. M., Funderburk, F. R., & Griffiths, R. R. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23193-7 · Cited by 165
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
Sanger, D. J., Benavides, J., Perrault, G., Morel, E., Cohen, C., Joly, D., & Zivkovic, B. (1994) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)90049-3 · Cited by 161
Finkle, W. D., Der, J. S., Greenland, S., Adams, J., Ridgeway, G. K., Blaschke, T. F., Wang, Z., Dell, R. M., & VanRiper, K. B. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03591.x · Cited by 155
Socioeconomic Impact of Insomnia in Working Populations
Metlaine, A., Léger, D., & Choudat, D. (2005) · Industrial Health · doi:10.2486/indhealth.43.11 · Cited by 155
Hoque, R., & Chesson, A. L. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27605 · Cited by 145
The safety and tolerability of zolpidem — an update
DARCOURT, G., Pringuey, D., Sallière, D., & Lavoisy, J. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300109 · Cited by 139
Philip, P., Sagaspe, P., Taillard, J., Moore, N. D., Guilleminault, C., Sánchez-Ortuño, M. M., Åkerstedt, T., & Bioulac, B. H. (2003) · SLEEP · doi:10.1093/sleep/26.3.277 · Cited by 137
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Duan, S. X., Grassi, J. M., Venkatakrishnan, K., Harmatz, J. S., & Shader, R. I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00953.x · Cited by 133
Self-citationOtmani, S., Demazières, A., Staner, C., Jacob, N., Nir, T., Zisapel, N., & Staner, L. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.980 · Cited by 133
Greenblatt, D. J., Harmatz, J. S., Moltke, L. L., Wright, C. E., Durol, A. L. B., Harrel-Joseph, L. M., & Shader, R. I. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39253-5 · Cited by 131
Self-citationTamblyn, R. M., Abrahamowicz, M., du Berger, R., McLeod, P. J., & Bartlett, G. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53108.x · Cited by 128
Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs
Greenblatt, D. J., & Moltke, L. L. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323754 · Cited by 126
Self-citationSleep disorders, sleepiness and traffic safety: a public health menace
Pandi-Perumal, S. R., Verster, J. C., Kayumov, L., Lowe, A. D., Santana, M. G., Pires, M. L. N., Tufik, S., & de Mello, M. T. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000700003 · Cited by 124
Zint, K., Haefeli, W. E., Glynn, R. J., Mogun, H., Avorn, J., & Stürmer, T. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2031 · Cited by 122
The Road to Danger: The Comparative Risks of Driving While Sleepy
Powell, N. B., Schechtman, K. B., Riley, R. W., Li, K. K., Troell, R. J., & Guilleminault, C. (2001) · The Laryngoscope · doi:10.1097/00005537-200105000-00024 · Cited by 122
Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon
Hesse, L. M., Moltke, L. L., & Greenblatt, D. J. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00004 · Cited by 120
Self-citationRoth, T. G., Soubrane, C., Titeux, L., & Walsh, J. K. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.04.008 · Cited by 120
Self-citationCorrelates and consequences of chronic insomnia
Thase, M. E. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2004.09.006 · Cited by 117
Benzodiazepine-Like Hypnotics and the Associated Risk of Road Traffic Accidents
Orriols, L., Philip, P., Moore, N. D., Castot, A., Gadegbeku, B., Delorme, B., Mallaret, M., & Lagarde, E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.3 · Cited by 117
Comparative Pharmacokinetic Profile of Two Imidazopyridine Drugs: Zolpidem and Alpidem
Durand, A., Thenot, J. P., Bianchetti, G., & Morselli, P. L. (1992) · Drug Metabolism Reviews · doi:10.3109/03602539208996294 · Cited by 115
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo*
Greenblatt, D. J., Harmatz, J. S., Moltke, L. L., Ehrenberg, B. L., Harrel, L., Corbett, K., Counihan, M., Graf, J. A., Darwish, M., Mertzanis, P., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90139-4 · Cited by 114
Self-citationSedative, memory, and performance effects of hypnotics
Roehrs, T., Merlotti, L. A., Zorick, F. J., & Roth, T. G. (1994) · Psychopharmacology · doi:10.1007/bf02245054 · Cited by 113
Self-citationOlubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01852.x · Cited by 104
Self-citationDifferential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Durol, A. L. B., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200006010-00007 · Cited by 103
Self-citationTroy, S. M., Lucki, I., Unruh, M., Cevallos, W. H., Leister, C. A., Martin, P. T., Furlan, P., & Mangano, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00007 · Cited by 99
Comparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98 · cited 1×
“Adverse reactions to zolpidem [65-69] generally are predictable consequences of its GABA-BZ agonist effects (Section 5).”
BackgroundChang, C., Chen, M., Tsai, C.-Y., Ho, L., Hsieh, H.-L., Chau, Y., & Liu, C.-Y. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2569 · Cited by 98
Zolpidem, Triazolam, and Temazepam
Rush, C. R., & Griffiths, R. R. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00007 · Cited by 98
Roehrs, T., Randall, S., Harris, E. J., Maan, R., & Roth, T. G. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424455 · Cited by 97
Self-citationVerster, J. C., Veldhuijzen, D. S., Patat, A. A., Olivier, B., & Volkerts, E. R. (2006) · Current Drug Safety · doi:10.2174/157488606775252674 · Cited by 95
Monti, J. M., Attali, P., Monti, D., Zipfel, A., Giclais, B. D. L., & Morselli, P. L. (1994) · Pharmacopsychiatry · doi:10.1055/s-2007-1014298 · Cited by 92
Effect of hypnotic drugs on body balance and standing steadiness
Mets, M. A. J., Volkerts, E. R., Olivier, B., & Verster, J. C. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2009.10.008 · Cited by 89 · cited 1×
“Given the pharmacodynamic similarity between zolpidem and other benzodiazepine hypnotics [88,89], it is not surprising that a link between zolpidem use and hip fractures has been reported as well [90-94].”
BackgroundGriebel, G., Perrault, G., Letang, V., Granger, P., Avenet, P., Schoemaker, H., & Sanger, D. J. (1999) · Psychopharmacology · doi:10.1007/s002130051108 · Cited by 86
Sleep driving: Sleepwalking variant or misuse of z-drugs?
Pressman, M. R. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.12.004 · Cited by 84
Zolpidem Ingestion, Automatisms, and Sleep Driving: A Clinical and Legal Case Series
Poceta, J. S. (2011) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.1468 · Cited by 84
Use of Non-Benzodiazepine Hypnotics in the Elderly: Are All Agents the Same?
Dolder, C. R., Nelson, M., & McKinsey, J. (2007) · CNS Drugs · doi:10.2165/00023210-200721050-00003 · Cited by 81
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole*
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Mertzanis, P., Graf, J. A., Durol, A. L. B., Counihan, M., Roth‐Schechter, B. F., & Shader, R. I. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90057-1 · Cited by 81
Self-citationStaner, L., Ertle, S., Boeijinga, P. H., Rinaudo, G., Arnal, M. A., Muzet, A. G., & Luthringer, R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0082-8 · Cited by 81
Rhalimi, M., Hélou, R., & Jaecker, P. (2009) · Drugs & Aging · doi:10.2165/11317610-000000000-00000 · Cited by 79
The Dose Effects of Zolpidem on the Sleep of Healthy Normals
Merlotti, L. A., Roehrs, T., Koshorek, G., Zorick, F. J., Lamphere, J. K., & Roth, T. G. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198902000-00003 · Cited by 79
Self-citationThe Impact of Benzodiazepines on Safe Driving
Dubois, S. J., Bédard, M., & Weaver, B. (2008) · Traffic Injury Prevention · doi:10.1080/15389580802161943 · Cited by 77
D, M. F. M., Asnis, G. M., Shrivastava, R. K., Lydiard, B., Bastani, B., Sheehan, D. V., & Roth, T. G. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a390ba · Cited by 76
Self-citationGustavsen, I., Al-Sammurraie, M., Mørland, J. G., & Bramness, J. G. (2009) · Accident Analysis & Prevention · doi:10.1016/j.aap.2009.01.011 · Cited by 76
Hajak, G., & Bandelow, B. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199807000-00002 · Cited by 76
Frey, D. J., Ortega, J. D., Wiseman, C., Farley, C. T., & Wright, K. P. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.03229.x · Cited by 75
Minimal Rebound Insomnia After Treatment with 10-mg Zolpidem
Ware, J. C., Walsh, J. K., Scharf, M. B., Roehrs, T., Roth, T. G., & Vogel, G. W. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00002 · Cited by 75
Self-citationPharmacokinetic and Pharmacodynamic Interactions Between Zolpidem and Caffeine
Cysneiros, R. M., Farkas, D., Harmatz, J. S., Moltke, L. L., & Greenblatt, D. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100211 · Cited by 72
Self-citationEfficacy and Safety of Zolpidem Extended Release in Elderly Primary Insomnia Patients
Walsh, J. K., Soubrane, C., & Roth, T. G. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181256b01 · Cited by 71
Self-citationJones, A. W., Holmgren, A., & Kugelberg, F. C. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31803d3c04 · Cited by 70
Zolpidem and Traffic Safety - The Importance of Treatment Compliance
Verster, J. C., Volkerts, E. R., Olivier, B., Johnson, W. D., & Liddicoat, L. J. (2007) · Current Drug Safety · doi:10.2174/157488607781668882 · Cited by 69
A postmarketing study of relative abuse liability of hypnotic sedative drugs
Jaffe, J. H., Bloor, R. N., CROME, I. B., Carr, M., Alam, F., Simmons, A., & Meyer, R. E. (2004) · Addiction · doi:10.1111/j.1360-0443.2003.00631.x · Cited by 67
de Haas, S., Schoemaker, R. C., van Gerven, J., Hoever, P., Cohen, A., & Dingemanse, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106898 · Cited by 65
Rifampin reduces plasma concentrations and effects of zolpidem*
Villikka, K., Kivistö, K. T., Luurila, H., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90082-5 · Cited by 64
Comparison of the daytime sleep and performance effects of zolpidem versus triazolam
Balkin, T. J., OʼDonnell, V. M., Wesensten, N. J., McCann, U. D., & Belenky, G. L. (1992) · Psychopharmacology · doi:10.1007/bf02244970 · Cited by 61
Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia.
Hoehns, J. D., & Perry, P. J. (1993) · PubMed · Cited by 60
Follesa, P., Mancuso, L., Biggio, F., Cagetti, E., Franco, M., TRAPANI, G., & Biggio, G. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00167-8 · Cited by 60
Ator, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59
EEG profile of intravenous zolpidem in healthy volunteers
Patat, A. A., Trocherie, S., Thébault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Court, L. A., & Morselli, P. L. (1994) · Psychopharmacology · doi:10.1007/bf02245455 · Cited by 59
Population study of triazolam pharmacokinetics.
Friedman, H. L., Greenblatt, D. J., Burstein, E., Harmatz, J. S., & Shader, R. I. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb02951.x · Cited by 58
Self-citationRoth, T. G., Hull, S. G., Lankford, D. A., Rosenberg, R. P., Scharf, M. B., Intermezzo Study Group, Nikhilesh Singh, P., Jenny Novack, B., Murray Maytom, M., Yu Ping Maguire, P., et al. (2008) · SLEEP · doi:10.5665/sleep/31.9.1277 · Cited by 56
Self-citationGreenblatt, D. J., Legangneux, E., Harmatz, J. S., Weinling, E., Freeman, J., Rice, K., & Zammit, G. K. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006293303 · Cited by 56
Self-citationKleykamp, B. A., Griffiths, R. R., McCann, U. D., Smith, M. T., & Mintzer, M. Z. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0025237 · Cited by 56
Yang, Y., Lai, J., Lee, C., Wang, J., & Chen, P. (2010) · Journal of Epidemiology · doi:10.2188/jea.je20090195 · Cited by 54
Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008
BEN-HAMOU, M., Marshall, N. S., Grunstein, R. R., Saini, B., & Fois, R. A. (2011) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2011.00919.x · Cited by 51
Sedative effects and impaired learning and recall after single oral doses of lorazepam
Shader, R. I., Dreyfuss, D. A., Gerrein, J. R., Harmatz, J. S., Allison, S. J., & Greenblatt, D. J. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.90 · Cited by 51
Self-citationA Large-Sample Study of Diazepam Pharmacokinetics
Greenblatt, D. J., Harmatz, J. S., Friedman, H. L., Locniskar, A., & Shader, R. I. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198911000-00007 · Cited by 49
Self-citationSchneeweiß, S., & Wang, P. S. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53303.x · Cited by 46
Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone
Byrnes, J. J., Greenblatt, D. J., & Miller, L. G. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90164-s · Cited by 46
Self-citationWeinling, E., McDougall, S. A., Andre, F., Bianchetti, G., & Dubruc, C. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00415.x · Cited by 46
Roehrs, T., Randall, S., Harris, E. J., Maan, R., & Roth, T. G. (2011) · SLEEP · doi:10.1093/sleep/34.2.207 · Cited by 43
Self-citationEffect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem
Luurila, H., Kivistö, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050439 · Cited by 39
Drug interaction between St John’s wort and zolpidem in healthy subjects
Hojo, Y., Echizenya, M., Ohkubo, T., & Shimizu, T. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01223.x · Cited by 38
General safety profile of zolpidem: safety in elderly, overdose and rebound effects
Allain, H., & Monti, J. M. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)80017-x · Cited by 37
Next day effects after nighttime treatment with zolpidem: a review
Undén, M., & Roth‐Schechter, B. F. (1996) · European Psychiatry · doi:10.1016/0924-9338(96)80465-2 · Cited by 37
Psychotropic Drug Prescribing in the United States: Extent, Costs, and Expenditures
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318209cf05 · Cited by 37
Self-citationFlumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic
Patat, A. A., Naef, M. M., Gessel, É. V., Forster, A., Dubruc, C., & Rosenzweig, P. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.157 · Cited by 35
Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P‐glycoprotein
Moltke, L. L., Weemhoff, J. L., Perloff, M. D., Hesse, L. M., Harmatz, J. S., Roth‐Schechter, B. F., & Greenblatt, D. J. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.329 · Cited by 34
Self-citationMinimal interaction between fluoxetine and multiple-dose zolpidem in healthy women.
Allard, S., Sainati, S. M., Roth‐Schechter, B. F., & MacIntyre, J. (1998) · PubMed · Cited by 32
Lahmeyer, H. W., Wilcox, C. S., Kann, J., & Leppik, I. E. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199713030-00003 · Cited by 30
Barkin, R. L. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31804c7292 · Cited by 30
Hajak, G., Hedner, J. A., Eglin, M., Loft, H., Stórustovu, S. I., Lütolf, S., & Lundahl, J. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.09.010 · Cited by 30
Rush, C. R., Armstrong, D. L., Ali, J. A., & Pazzaglia, P. J. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804000-00008 · Cited by 30
Farkas, D., Volak, L., Harmatz, J. S., Moltke, L. L., Court, M., & Greenblatt, D. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.293 · Cited by 27
Self-citationRoth, T. G., Mayleben, D. W., Corser, B. C., & Singh, N. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.884 · Cited by 27
Self-citationClinical Studies of Drug–Drug Interactions: Design and Interpretation
Greenblatt, D. J., & Moltke, L. L. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_24 · Cited by 26
Self-citationThe effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.
Piergies, A. A., Sweet, J., Johnson, M., Roth‐Schechter, B. F., & Allard, S. (1996) · PubMed · Cited by 25
Staner, L., Eriksson, M. B., Cornette, F., Santoro, F., Muscat, N., Luthinger, R., & Roth, T. G. (2008) · Sleep Medicine · doi:10.1016/j.sleep.2008.06.008 · Cited by 25
Self-citationPharmacokinetic Interaction Between Zolpidem and Carbamazepine in Healthy Volunteers
Vlase, L., Popa, A., Maria Adriana, N. E. A. G., Muntean, D. M., Bâldea, I., & Leucuta, S. E. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010383690 · Cited by 24
Olubodun, J. O. B., Ochs, H. R., Trüten, V., Klein, A., Moltke, L. L., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002237988 · Cited by 24
Self-citationMintzer, M. Z., Frey, J. M., & Griffiths, R. R. (1998) · Behavioural Pharmacology · doi:10.1097/00008877-199811000-00010 · Cited by 23
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects
Saari, T. I., Laine, K., Leino, K. A., Valtonen, M., Neuvonen, P. J., & Olkkola, K. T. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02707.x · Cited by 23
Efficacy of zolpidem in insomnia
Rg, P., Terzano, M., Parrino, L., & Boyer, P. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)80015-6 · Cited by 20
Polasek, T. M., Sadagopal, J. S., Elliot, D. J., & Miners, J. O. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0760-2 · Cited by 20
A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia
Staner, L., Danjou, P., & Luthringer, R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.197 · Cited by 19
Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers
Vlase, L., Popa, A., Maria Adriana, N. E. A. G., Muntean, D. M., & Leucuta, S. E. (2010) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-010-0014-9 · Cited by 17
Staner, C., Joly, F., Jacquot, N., Vlasova, I. D., Nehlin, M., Lundqvist, T., Edenius, C., & Staner, L. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003788225 · Cited by 15
Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine.
Hulhoven, R., Desager, J. P., Harvengt, C., Hermann, P., Guillet, P., & Thiercelin, J. F. (1988) · PubMed · Cited by 14
Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics
Greenblatt, D. J. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_4 · Cited by 10
Self-citationZolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties
Zammit, G. K. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.325 · Cited by 10
Introduction to Drug-Drug Interactions
Greenblatt, D. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-213-7_1 · Cited by 7
Self-citationSublingual zolpidem tartrate lozenge for the treatment of insomnia
Lankford, A. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.15 · Cited by 7
CYP enzyme system and its relevance to the pharmacology of sleep
Preskorn, I. D. A. S. H. (2008) · CRC Press eBooks · doi:10.3109/9780203091715-18 · Cited by 7
Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation
Moltke, L. L., & Greenblatt, D. J. (2009) · Wiley eBooks · doi:10.1002/9780470538951.ch17 · Cited by 6
Self-citation
Cited by
Fluorination methods in drug discovery
Yerien, D. E., Bonesi, S., & Postigo, A. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00764c · Cited by 348
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230
Greenblatt, D. J., Harmatz, J. S., Singh, N. N., Steinberg, F., Roth, T., Moline, M. L., Harris, S. C., & Kapil, R. P. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.220 · Cited by 107
Self-citationHypnotics in Insomnia: The Experience of Zolpidem
MacFarlane, J., Morin, C. M., & Montplaisir, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.017 · Cited by 94
Eliot, L., & Richardson, S. S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1391-16.2016 · Cited by 70
“However, subsequent analysis found that although zolpidem is cleared more slowly in nonelderly women, compared with nonelderly men (Greenblatt and Roth, 2012), differences in body weight, not sex/gender per se, mediate most of the male-female difference in human zolpidem metabolism (Greenblatt et al.”
Background
Metadata
- Authors
- Greenblatt, D. J., & Roth, T.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2012-03-19
- Volume
- 13
- Issue
- 6
- Pages
- 879-893
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2039579887
- Cited by
- 283
- References
- 150
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.